Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Vascular calcification and endothelial dysfunction (ED) contribute to the development of
cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a
non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification
in CKD patients while the exact mechanism has not been clarified.
This study was designed to investigate the effect of short-term sevelamer treatment on both
serum FGF23 levels concentrations and ED seen in CKD patients.
The researchers investigated the relationship between plasma FGF23 levels and the forearm
blood flow response to ischemia in the forearm in a sizable series of incident stage 3-4 CKD
patients.